Home  /  Resource Library  /  Lisocabtagene maraleucel as second line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study

Lisocabtagene maraleucel as second line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study

Results of a study examining CAR T therapy lisocabtagene maraleucel as second line treatment for relapsed large cell lymphomas. (Abstract only)